Intraoperative Radiotherapy (IORT) Market Global Report 2026

The intraoperative radiotherapy (IORT) market size has grown rapidly in recent years. It will grow from $1.08 billion in 2025 to $1.19 billion in 2026 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing cancer incidence, rising demand for targeted radiation treatment, growing preference for shorter treatment protocols, increasing investment in advanced oncology infrastructure, and rising adoption of image-guided surgical procedures.

The intraoperative radiotherapy (IORT) market size is expected to see rapid growth in the next few years. It will grow to $1.75 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth during the forecast period can be attributed to growing demand for personalized cancer treatment, increasing need to reduce radiation exposure to healthy tissue, rising adoption of intraoperative treatment technologies, expanding availability of specialized oncology centers, and growing demand for single-session radiation therapy. Major trends in the forecast period include increasing adoption of single-session cancer treatment approaches, rising demand for precise intraoperative radiation delivery, growing use of compact radiation therapy systems, increasing demand for integrated treatment planning and dosimetry, and rising adoption of minimally invasive cancer treatment procedures.

The rising prevalence of cancer is expected to propel the growth of the intraoperative radiotherapy (IORT) market going forward. Cancer is a group of diseases in which abnormal cells grow uncontrollably, invade tissues, and can spread to other parts of the body. Cancer prevalence is increasing due to the aging population, as advanced age is the most significant risk factor for developing most types of cancer, with the majority of cases occurring in individuals over 65 years old. Intraoperative radiotherapy (IORT) enhances cancer treatment by delivering a concentrated dose of radiation directly to the tumor bed during surgery, improving treatment precision, minimizing exposure to surrounding healthy tissues, and reducing the risk of local cancer recurrence. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the rising prevalence of cancer is driving the growth of the intraoperative radiotherapy market.

Major companies operating in the intraoperative radiotherapy (IORT) market are concentrating on developing innovative solutions, such as advanced intraoperative radiation delivery technologies, to improve treatment precision, reduce radiation exposure to healthy tissues, and enhance cancer treatment outcomes. Advanced intraoperative radiation delivery technologies are innovative systems that enable precise, real-time radiation delivery directly to a tumor or tumor bed during surgery, minimizing damage to surrounding healthy tissues and improving treatment accuracy. For instance, in October 2024, Aster DM Quality Care Limited, an India-based healthcare company, launched Intra-Operative Electron Radiation Therapy (IOeRT) at the Aster International Institute of Oncology, Aster Whitefield Hospital, Bengaluru, becoming the first healthcare institution in India to introduce this technology. The IOeRT system delivers concentrated electron radiation immediately after tumor removal, targeting residual microscopic cancer cells while preserving adjacent healthy tissues. It is particularly suitable for treating breast, gastrointestinal, lung, pancreatic, gynecologic, and soft tissue cancers where precision is essential. The technology can shorten overall treatment time by potentially replacing multiple postoperative radiation sessions with a single intraoperative dose, reduce radiation-related side effects, and support faster patient recovery while improving local tumor control.

In October 2023, Elekta AB, a Sweden-based medical technology company, acquired Xoft, a business line of iCAD, Inc., for $5.5 million. Through this acquisition, Elekta sought to expand its brachytherapy portfolio and treatment applications by adding electronic brachytherapy capabilities, increasing access to precision cancer treatments, and strengthening its ability to serve a broader range of oncology clinics and patients globally. Xoft is a US-based medical technology company that offers intraoperative radiotherapy (IORT) solutions for targeted radiation delivery during cancer surgery.

Major companies operating in the intraoperative radiotherapy (IORT) market are Thales Electron Devices SAS, Siemens Healthineers AG, Hologic Inc., Carl Zeiss Meditec AG, Elekta AB, Eckert & Ziegler Radiopharma GmbH, GMV Innovating Solutions S.L., Mevion Medical Systems Inc., Sensus Healthcare Inc., Tema Sinergie S.p.A., iCAD Inc., Xstrahl Ltd., IntraOp Medical Corporation, BEBIG Medical GmbH, S.I.T. Sordina IORT Technologies S.p.A.

North America was the largest region in the intraoperative radiotherapy (IORT) market in 2025. Asia-Pacifc is expected to be the fastest-growing region in the forecast period. The regions covered in the intraoperative radiotherapy (IORT) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the intraoperative radiotherapy (IORT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.